Advertisement

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Opportunities to Optimize Cancer Policies Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




May
04
Today In Oncology
Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer
Dose Escalation of Fluorodeoxyglucose PET Guided Radiotherapy for Locally Advanced NSCLC
Use of CAD CAM May Improve Jaw Reconstruction Outcomes Among Patients With Head and Neck Cancer
Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma
Applications Are Now Open for the 2025 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo